Source: PR Newswire

Thermogenesis received $2M in Post-IPO Equity Funding

Read full article »
Thermogenesis's Competitors | Thermogenesis's News | Thermogenesis's Financials

January 26, 2023

MarketScreener

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

(marketscreener.com) Bristol Myers Squibb today announced topline results from TRANSCEND CLL 004, a P... See more »

January 25, 2023

Acrofan

INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit - FATE

See more »

January 25, 2023

The Business Journals: New York

Novartis, HBK grab office space in Midtown

The property at 452 Fifth Ave. features two private elevators for senior executives and overlooks the... See more »
Thermogenesis's News
January 25, 2023Drug Store News

Gilead Sciences receives FDA OK for Sunlenca

Sunlenca is a new type of antiretroviral medication for adult patients living with HIV-1, whose HIV i... See more »
Thermogenesis's News
January 26, 2023FinSMEs

iVexSol Closes $23.8M Series A-3 Financing

iVexSol, a Lexington, MA-based technology-based lentiviral vector (LVV) contract development and manu... See more »
Thermogenesis's News
January 23, 2023Benzinga

Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate

Agenus Inc (NASDAQ: AGEN) announced clinical data from the MSS CRC (microsatellite stable colorectal ... See more »
Thermogenesis's News
January 25, 2023NewsFile

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE

New York, New York--(Newsfile Corp. - January 25, 2023) - Pomerantz LLP announces that a class action... See more »
Thermogenesis's News
January 25, 2023Endpoints News

Novartis re-enlists spokescelebrity Ken Jeong for Xiidra movie trailer spoof campaign

Pharma marketers are known for recruiting both doctors and celebrities for ad campaigns. But Novartis... See more »
Thermogenesis's News
January 25, 2023Law 360

Bristol Myers Settles Workers' Vax Exemption Claims

Two fired workers told a New York federal court they had reached an agreement with Bristol Myers Squi... See more »

January 26, 2023

MarketScreener

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

(marketscreener.com) Bristol Myers Squibb today announced topline results from TRANSCEND CLL 004, a P... See more »

January 25, 2023

Acrofan

INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit - FATE

See more »

January 25, 2023

The Business Journals: New York

Novartis, HBK grab office space in Midtown

The property at 452 Fifth Ave. features two private elevators for senior executives and overlooks the... See more »
Thermogenesis's News
January 25, 2023Drug Store News

Gilead Sciences receives FDA OK for Sunlenca

Sunlenca is a new type of antiretroviral medication for adult patients living with HIV-1, whose HIV i... See more »
Thermogenesis's News
January 26, 2023FinSMEs

iVexSol Closes $23.8M Series A-3 Financing

iVexSol, a Lexington, MA-based technology-based lentiviral vector (LVV) contract development and manu... See more »
Thermogenesis's News
January 23, 2023Benzinga

Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate

Agenus Inc (NASDAQ: AGEN) announced clinical data from the MSS CRC (microsatellite stable colorectal ... See more »
Thermogenesis's News
January 25, 2023NewsFile

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE

New York, New York--(Newsfile Corp. - January 25, 2023) - Pomerantz LLP announces that a class action... See more »
Thermogenesis's News
January 25, 2023Endpoints News

Novartis re-enlists spokescelebrity Ken Jeong for Xiidra movie trailer spoof campaign

Pharma marketers are known for recruiting both doctors and celebrities for ad campaigns. But Novartis... See more »
Thermogenesis's News
January 25, 2023Law 360

Bristol Myers Settles Workers' Vax Exemption Claims

Two fired workers told a New York federal court they had reached an agreement with Bristol Myers Squi... See more »
Stay up-to-date with the latest news on Thermogenesis
Annual Revenue
$9.3M
Employees
40
Chris Xu's photo - Chairman & CEO of Thermogenesis

Chairman & CEO

Chris Xu

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Thermogenesis